Wilson P - Search Results

1

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.

Gordon MA, Zhang W, Yang D, Iqbal S, El-Khouiery A, Nagashima F, Lurje G, Labonte M, Wilson P, Sherrod A, Ladner RD, Lenz HJ. Gordon MA, et al. Among authors: wilson p. Pharmacogenomics. 2011 Jan;12(1):27-39. doi: 10.2217/pgs.10.163. Pharmacogenomics. 2011. PMID: 21174620 Free PMC article.

2

Exploring alternative individualized treatment strategies in colorectal cancer.

Wilson PM, Ladner RD, Lenz HJ. Wilson PM, et al. Clin Colorectal Cancer. 2007 Dec;7 Suppl 1:S28-36. doi: 10.3816/ccc.2008.s.005. Clin Colorectal Cancer. 2007. PMID: 18361804 Review.

3

Novel opportunities for thymidylate metabolism as a therapeutic target.

Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD. Wilson PM, et al. Mol Cancer Ther. 2008 Sep;7(9):3029-37. doi: 10.1158/1535-7163.MCT-08-0280. Mol Cancer Ther. 2008. PMID: 18790783 Free PMC article.

4

Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage.

Wilson PM, Fazzone W, LaBonte MJ, Lenz HJ, Ladner RD. Wilson PM, et al. Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16. Nucleic Acids Res. 2009. PMID: 19015155 Free PMC article.

5

Polymorphisms in cyclooxygenase-2 and epidermal growth factor receptor are associated with progression-free survival independent of K-ras in metastatic colorectal cancer patients treated with single-agent cetuximab.

Lurje G, Nagashima F, Zhang W, Yang D, Chang HM, Gordon MA, El-Khoueiry A, Husain H, Wilson PM, Ladner RD, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ. Lurje G, et al. Clin Cancer Res. 2008 Dec 1;14(23):7884-95. doi: 10.1158/1078-0432.CCR-07-5165. Clin Cancer Res. 2008. PMID: 19047118

6

Predictive and prognostic markers in colorectal cancer.

Wilson PM, Ladner RD, Lenz HJ. Wilson PM, et al. Gastrointest Cancer Res. 2007 Nov;1(6):237-46. Gastrointest Cancer Res. 2007. PMID: 19262902 Free PMC article.

7

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.

Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD. Fazzone W, et al. Int J Cancer. 2009 Jul 15;125(2):463-73. doi: 10.1002/ijc.24403. Int J Cancer. 2009. PMID: 19384949

8

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.

LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD. LaBonte MJ, et al. Int J Cancer. 2009 Dec 15;125(12):2957-69. doi: 10.1002/ijc.24658. Int J Cancer. 2009. PMID: 19536776

9

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD. LaBonte MJ, et al. BMC Med Genomics. 2009 Nov 30;2:67. doi: 10.1186/1755-8794-2-67. BMC Med Genomics. 2009. PMID: 19948057 Free PMC article.

10

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.

Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ. Wilson PM, et al. Cancer Chemother Pharmacol. 2010 Apr;65(5):979-88. doi: 10.1007/s00280-009-1236-x. Cancer Chemother Pharmacol. 2010. PMID: 20062993 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,461 results

Search Page

Filters